Abstract
A 61-year-old man treated with an autologous transplant for multiple myeloma was incidentally found to have a high level of BCR-ABL fusion gene-positive cells in his bone marrow. We describe the clinical decision-making process that led us to initiate therapy with imatinib, despite the absence of any clinical evidence of chronic myelogenous leukemia or other BCR-ABL associated hematologic malignancy.
MeSH terms
-
Bone Marrow Transplantation / methods*
-
Bone Marrow*
-
Fusion Proteins, bcr-abl / analysis*
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Male
-
Middle Aged
-
Multiple Myeloma / complications*
-
Multiple Myeloma / diagnosis
-
Multiple Myeloma / therapy
-
Remission Induction / methods
-
Transplantation, Autologous